Skip to main content

Bristol Myers Squibb ratios

  • BMY · NYSE
  • Pharmaceuticals
  • S&P 500
$63.43+1.78%Close 13 Nov 2026 · Market value $128.9B

In fiscal 2025 (the year to 31 Dec 2025), Bristol Myers Squibb had an operating margin of 20.8%, a return on equity of 40.5%, a return on invested capital of 11.5%.

From Bristol Myers Squibb's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025.

Annual

Bristol Myers Squibb ratios, annual
USDFY 2007FY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Gross margin68.5%70.0%72.7%72.9%73.6%73.8%71.8%75.2%76.4%74.5%70.7%71.3%69.1%72.3%78.6%78.0%76.2%71.1%71.1%
Operating margin—28.7%30.8%31.9%33.5%14.3%18.9%16.3%13.7%31.3%25.6%22.7%22.6%−21.6%15.9%18.0%16.2%−15.5%20.8%
Net margin13.9%29.6%56.4%15.9%17.5%11.1%15.6%12.6%9.5%22.9%4.8%21.8%13.2%−21.2%15.1%13.7%17.8%−18.5%14.6%
Free cash flow margin14.8%15.6%17.7%20.9%21.1%36.3%18.4%16.5%7.8%9.5%20.3%27.1%28.2%31.3%32.8%25.9%28.1%28.9%26.7%
Return on equity—42.9%78.4%20.3%23.4%13.3%17.8%13.4%10.7%29.3%7.2%38.2%10.5%−20.2%19.0%18.9%26.5%−39.1%40.5%
Return on assets—13.3%15.1%14.9%16.8%5.8%7.4%6.1%5.4%14.2%12.5%12.4%5.0%−5.8%5.6%6.6%7.2%−6.3%8.3%
Return on capital employed—22.3%24.4%25.4%28.8%9.6%11.5%10.0%9.2%25.0%21.8%21.2%8.7%−8.7%7.9%10.2%9.9%−10.6%14.8%
Return on invested capital—26.3%28.3%26.3%30.1%8.7%11.1%10.5%8.6%21.9%20.8%21.2%6.5%−7.3%7.2%8.3%9.4%−8.7%11.5%
Current ratio—2.192.211.971.971.151.521.731.301.551.551.661.601.581.521.251.431.251.26
Debt to equity—0.550.430.350.340.590.550.530.470.410.680.610.971.421.401.441.513.252.66
Net debt / EBITDA—−0.27−0.34−0.27−0.421.630.820.130.920.030.19−0.034.5631.671.851.901.8819.952.74
Interest coverage—16.4131.4542.8749.1413.8615.5312.7312.2936.4227.1827.959.01−6.475.536.736.25−3.845.29
Cash conversion107%52.7%31.4%131%121%326%117%131%82.1%41.4%419%124%214%−148%218%189%158%−156%182%
Dividend payout102%46.9%23.4%71.0%60.8%117%90.1%120%158%57.1%256%53.1%77.9%—62.9%73.2%59.1%—71.5%
SBC / Revenue0.9%1.0%1.0%1.0%0.8%0.9%1.2%1.3%1.4%1.1%1.0%1.0%1.7%1.8%1.3%1.0%1.2%1.0%1.1%

Quarterly

Bristol Myers Squibb ratios, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Gross margin76.1%75.3%73.2%75.1%61.0%72.9%72.5%71.9%67.2%70.2%71.3%68.3%
Operating margin11.4%−96.4%12.8%16.1%3.9%29.6%18.5%24.6%11.4%28.5%31.0%21.8%
Net margin15.4%−100%13.8%10.2%0.6%21.9%10.7%18.0%8.7%23.3%25.6%16.5%
Free cash flow margin34.2%21.5%16.9%44.3%32.9%15.1%29.0%49.0%12.8%6.6%23.8%29.4%
Return on equity6.0%−72.2%9.9%7.1%0.4%14.1%7.5%11.9%5.9%13.3%14.9%9.2%
Return on assets1.1%−9.1%1.3%1.5%0.2%3.0%1.8%2.2%1.2%3.1%3.7%2.7%
Return on capital employed1.8%−15.6%2.2%2.7%0.7%4.8%3.4%4.4%2.1%4.9%5.8%4.1%
Return on invested capital1.5%−11.3%1.7%2.0%0.3%4.0%2.4%3.0%1.6%4.2%5.3%4.0%
Current ratio1.431.111.161.241.251.281.211.271.261.421.531.59
Debt to equity1.513.663.363.053.253.143.182.982.662.412.051.95
Net debt / EBITDA8.51—12.249.8717.879.9012.689.6216.049.817.509.47
Interest coverage4.12−26.912.993.780.976.704.676.263.287.969.897.05
Cash conversion223%−21.4%123%435%5640%69.0%271%272%148%28.3%93.1%177%
Dividend payout65.8%—72.4%100%1692%51.2%96.3%57.4%116%47.9%38.8%59.5%
SBC / Revenue1.1%1.1%1.0%1.1%1.0%1.3%1.1%1.1%1.1%1.3%1.0%1.1%

The main figures as JSON and plain text. See data and methodology.

BMY in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.